CA-FORESCOUT-TECH
14.6.2022 12:02:08 CEST | Business Wire | Press release
Forescout Technologies , the leader in automated cybersecurity, today announced the expansion of its Envision Channel Program, launching a new Managed Service Provider (MSP) Partner Program to support customers with enhanced technical and professional service capabilities.
Designed to offer Forescout’s most experienced and technically competent partners new flexible licensing options, consumption billing, and specialized resources, the MSP program expansion improves the partner-owned customer deployment and support experience. Forescout Partners, such as BT and Accenture, were instrumental in driving program enhancements to meet the increasing security challenges of their global customers.
Kevin Brown, Managing Director, Security for BT, said: “Cybersecurity is top of mind for our customers, who all want to ensure they’ve got the best protections for their most critical assets. BT has partnered with Forescout for several years, and we have more than 50 Forescout-accredited technical professionals supporting customer deployments around the world. This new program enhancement aligns with our customers’ demand for faster, more integrated solutions that tackle the changing threat landscape and enable their opportunities.”
“Forescout’s channel program has played a pivotal role in our company’s business journey. Our channel partners have helped countless enterprises around the globe obtain more visibility of their cyber assets to quickly mitigate critical risks,” said Keith Weatherford, vice president of worldwide channel sales, Forescout. “The evolving digital terrain is creating new demand to activate Forescout services and capabilities so these new initiatives will provide a seamless set of training and enablement resources to support them on this path.”
“We see this program as a great extension of the value we have been delivering to clients in partnership with Forescout,” said Jamie Bass, Managing Director, Security, Accenture. “Allowing an organization to more easily leverage Forescout’s industry leading capabilities in network visibility as a service supported by our global delivery team reduces the requirement to hire and train an organization’s own team to deploy and run the solution.”
The Forescout Envision Channel Program now encompasses:
- Managed Services and Service Delivery Partner Program: Exclusively for partners who have demonstrated a high level of technical expertise and proficiency when deploying and supporting the Forescout platform. It provides highly qualified partners with flexible licensing and billing options in exchange for owning the customer support experience
- Updated Partner Portal and New Forescout Academy Platform: Quick access to digitally rich learning resources and assets to demonstrate and be recognized for technical competencies across the Forescout platform and broad set of capabilities.
- Partner Learning Journey Expansion: As part of the new direction for the Envision Channel Program, Forescout has developed an Accredited Engineer course for technical partner staff to be introduced to the Forescout Continuum Platform. Additionally, it has created the Forescout Forerunner Program which recognizes partners who accelerate onboarding and service delivery for client end-users.
With its new accreditations for partner engineer and technical support and new Managed Service Program, Forescout is recognizing and rewarding its global partner ecosystem to drive new earning opportunities and recognize the value add that they bring to the company’s success.
To learn more about Forescout’s Envision Channel Program, visit: https://www.forescout.com/resources/managed-service-provider-partner-program-overview/
About Forescout
Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides 100% asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005091/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom